-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
-
Summary
-
Alnylam Pharmaceuticals, Inc. quarterly Deferred Income Tax Assets, Net history and growth rate from Q4 2023 to Q3 2025.
- Alnylam Pharmaceuticals, Inc. Deferred Income Tax Assets, Net for the quarter ending September 30, 2025 was $98.6M.
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Growth (%)